memantine has been researched along with Multiple Sclerosis, Relapsing-Remitting in 3 studies
Multiple Sclerosis, Relapsing-Remitting: The most common clinical variant of MULTIPLE SCLEROSIS, characterized by recurrent acute exacerbations of neurologic dysfunction followed by partial or complete recovery. Common clinical manifestations include loss of visual (see OPTIC NEURITIS), motor, sensory, or bladder function. Acute episodes of demyelination may occur at any site in the central nervous system, and commonly involve the optic nerves, spinal cord, brain stem, and cerebellum. (Adams et al., Principles of Neurology, 6th ed, pp903-914)
| Excerpt | Relevance | Reference |
|---|---|---|
| " In addition, many adverse reactions were observed in these patients." | 2.82 | Efficacy and safety profile of memantine in patients with cognitive impairment in multiple sclerosis: A randomized, placebo-controlled study. ( Brassat, D; Brochet, B; Cabre, P; Castelnovo, G; Clavelou, P; Coman, I; Creveuil, C; Daplaud, D; De Seze, J; Debouverie, M; Defer, G; Dupuy, B; Hautecoeur, P; Heinzlef, O; Lebiez, P; Lebrun-Frenay, C; Pelletier, J; Peyro Saint Paul, L; Sartori, É; Tourbah, A; Vermersch, P, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Peyro Saint Paul, L | 1 |
| Creveuil, C | 1 |
| Heinzlef, O | 1 |
| De Seze, J | 1 |
| Vermersch, P | 1 |
| Castelnovo, G | 1 |
| Cabre, P | 1 |
| Debouverie, M | 1 |
| Brochet, B | 1 |
| Dupuy, B | 1 |
| Lebiez, P | 1 |
| Sartori, É | 1 |
| Clavelou, P | 1 |
| Brassat, D | 1 |
| Lebrun-Frenay, C | 1 |
| Daplaud, D | 1 |
| Pelletier, J | 1 |
| Coman, I | 1 |
| Hautecoeur, P | 1 |
| Tourbah, A | 1 |
| Defer, G | 1 |
| Villoslada, P | 1 |
| Arrondo, G | 1 |
| Sepulcre, J | 1 |
| Alegre, M | 1 |
| Artieda, J | 1 |
| Green, AJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Memantine on Cognitive Disorders of Relapsing-remitting Multiple Sclerosis[NCT01074619] | Phase 3 | 90 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| Pilot Clinical Trial With Memantine for Cognitive Deficits in Patients With Multiple Sclerosis[NCT00638833] | Phase 2 | 20 participants (Actual) | Interventional | 2007-09-30 | Terminated (stopped due to Unexpected side-effects: reversible and mild to moderate neurological impairment) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for memantine and Multiple Sclerosis, Relapsing-Remitting
| Article | Year |
|---|---|
Efficacy and safety profile of memantine in patients with cognitive impairment in multiple sclerosis: A randomized, placebo-controlled study.
Topics: Adult; Cognition Disorders; Dizziness; Double-Blind Method; Excitatory Amino Acid Antagonists; Femal | 2016 |
Memantine induces reversible neurologic impairment in patients with MS.
Topics: Brain; Cognition Disorders; Cross-Over Studies; Disability Evaluation; Dose-Response Relationship, D | 2009 |
1 other study available for memantine and Multiple Sclerosis, Relapsing-Remitting
| Article | Year |
|---|---|
Understanding pseudo: the symptoms are real, the cause is unclear.
Topics: Brain; Chemotaxis, Leukocyte; Clinical Trials as Topic; Encephalitis; Excitatory Amino Acid Antagoni | 2009 |